Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings
Open Access
- 25 March 2008
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 98 (8), 1336-1341
- https://doi.org/10.1038/sj.bjc.6604266
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Developing a Rational Tumor Vaccine Therapy for Renal Cell Carcinoma: Immune Yin and YangClinical Cancer Research, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-α-2bCancer, 2006
- Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II StudyTransplantation and Cellular Therapy, 2006
- Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago ExperienceBone Marrow Transplantation, 2004
- Clinical and Immunologic Effects of Subcutaneously Administered Interleukin-12 and Interferon Alfa-2b: Phase I Trial of Patients With Metastatic Renal Cell Carcinoma or Malignant MelanomaJournal of Clinical Oncology, 2004
- Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal CancerJournal of Clinical Oncology, 2003
- Placebo‐associated remissions in a multicentre, randomized, double‐blind trial of interferon γ‐1b for the treatment of metastatic renal cell carcinomaBJU International, 2000
- A Mechanism for the Specific Immunogenicity of Heat Shock Protein-Chaperoned PeptidesScience, 1995
- The serologically unique cell surface antigen of zajdela ascitic hepatoma is also its tumor‐associated transplantation antigenInternational Journal of Cancer, 1984